Long noncoding RNAs (lncRNAs) play essential roles in the occurrence and development of multiple human cancers. An accumulating body of researches have investigated thymopoietin antisense RNA 1 (TMPO-AS1) as a newly discovered lncRNA, which functions as an oncogenic lncRNA that is upregulated in various human malignancies and associated with poor prognosis. Many studies have detected abnormally high expression levels of TMPO-AS1 in multiple cancers, such as lung cancer, breast cancer, colorectal cancer (CRC), hepatocellular carcinoma, CRC, gastric cancer, ovarian cancer, thyroid cancer, esophageal cancer, Wilms tumor, cervical cancer, retinoblastoma, bladder cancer, osteosarcoma, and prostate cancer. TMPO-AS1 has been subsequently demonstrated to play a pivotal role in tumorigenesis and progression. The aberrantly expressed TMPO-AS1 acts as a competing endogenous RNA (ceRNA) that inhibits miRNA expression, thus activating the expression of downstream oncogenes. This study comprehensively summarizes the aberrant expressions of TMPO-AS1 as reported in the current literature and explains the relevant biological regulation mechanisms in carcinogenesis and tumor progression. Corresponding studies have indicated that TMPO-AS1 has a potential value as a promising biomarker or a target for cancer therapy.

中文翻译：

---

胸腺生成素-反义 RNA 1 作为长链非编码 RNA 在人类癌症发病机制中的新作用

长链非编码 RNA (lncRNA) 在多种人类癌症的发生和发展中发挥着重要作用。越来越多的研究调查了胸腺生成素反义 RNA 1 (TMPO-AS1) 作为一种新发现的 lncRNA，它作为致癌 lncRNA 在各种人类恶性肿瘤中上调并与不良预后相关。多项研究检测到TMPO-AS1在多种癌症中异常高表达，如肺癌、乳腺癌、结直肠癌（CRC）、肝细胞癌、CRC、胃癌、卵巢癌、甲状腺癌、食管癌、肾母细胞瘤、宫颈癌、视网膜母细胞瘤、膀胱癌、骨肉瘤和前列腺癌。随后证明 TMPO-AS1 在肿瘤发生和进展中起关键作用。异常表达的 TMPO-AS1 充当竞争性内源 RNA (ceRNA)，抑制 miRNA 表达，从而激活下游癌基因的表达。本研究全面总结了现有文献报道的TMPO-AS1的异常表达，并解释了致癌和肿瘤进展的相关生物学调控机制。相应的研究表明，TMPO-AS1 具有作为有前景的生物标志物或癌症治疗靶点的潜在价值。